NEW YORK (GenomeWeb News) – Sigma-Aldrich and Sangamo BioSciences today announced an expansion of their licensing deal covering zinc finger DNA binding protein-modified cell lines.

Under the new pact, Sigma-Aldrich gains exclusive rights to develop and distribute the ZFP-modified cell lines for commercial production of protein pharmaceuticals. In addition, Sigma-Aldrich has rights to certain ZFP-engineered transgenic animals for commercial applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.